X
Record #12734

Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566

Publisher
Wiley
Original paper date
Feb 17, 2017
Original DOI
10.1111/gbb.12373
Institution
Biomedicine Division, Centre for Systems Biotechnology, Fraunhofer Research Foundation, Santiago, Chile · Gen.DDI Ltd, London, UK · Laboratory of Molecular Neuropsychiatry, Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, National Scientific and Technical Research Council, Buenos Aires, Argentina · Division of Brain Sciences, Centre for Neuroinflammation and Neurodegeneration, Imperial College, London, UK · Facultad de Ciencias, Universidad de Chile, Santiago, Chile · AMO Pharmaceuticals Ltd, Huntingdon, UK · Facultad de Ingeniería y Ciencias, Universidad Adolfo Ibañez, Santiago, Chile, and §§Neuren Pharmaceuticals, Bethesda, MD, USA · Institute Of Ecology and Biodiversity (IEB), Faculty of Science, University of Chile, Santiago, Chile · Neuro-DVI LLP, London, UK
Open access
No
Article type
Research Article
Broad categories
(BLS) Biochemistry(BLS) Biology - Cellular(BLS) Biology - Molecular(BLS) Genetics
Citation lifecycle

How this paper is being cited

Pre-retraction
0
Same day
0
Post-retraction
5
% post-retraction
100.0%
~0.0 citations/yr before retraction · ~0.6 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse